These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
324 related articles for article (PubMed ID: 26407030)
1. Solubility Challenges in High Concentration Monoclonal Antibody Formulations: Relationship with Amino Acid Sequence and Intermolecular Interactions. Pindrus M; Shire SJ; Kelley RF; Demeule B; Wong R; Xu Y; Yadav S Mol Pharm; 2015 Nov; 12(11):3896-907. PubMed ID: 26407030 [TBL] [Abstract][Full Text] [Related]
2. Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions. Nichols P; Li L; Kumar S; Buck PM; Singh SK; Goswami S; Balthazor B; Conley TR; Sek D; Allen MJ MAbs; 2015; 7(1):212-30. PubMed ID: 25559441 [TBL] [Abstract][Full Text] [Related]
3. Viscosity of high concentration protein formulations of monoclonal antibodies of the IgG1 and IgG4 subclass - prediction of viscosity through protein-protein interaction measurements. Neergaard MS; Kalonia DS; Parshad H; Nielsen AD; Møller EH; van de Weert M Eur J Pharm Sci; 2013 Jun; 49(3):400-10. PubMed ID: 23624326 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic Antibody Engineering To Improve Viscosity and Phase Separation Guided by Crystal Structure. Chow CK; Allan BW; Chai Q; Atwell S; Lu J Mol Pharm; 2016 Mar; 13(3):915-23. PubMed ID: 26849155 [TBL] [Abstract][Full Text] [Related]
5. Intermolecular interactions of IgG1 monoclonal antibodies at high concentrations characterized by light scattering. Scherer TM; Liu J; Shire SJ; Minton AP J Phys Chem B; 2010 Oct; 114(40):12948-57. PubMed ID: 20849134 [TBL] [Abstract][Full Text] [Related]
7. Cosolute effects on the chemical potential and interactions of an IgG1 monoclonal antibody at high concentrations. Scherer TM J Phys Chem B; 2013 Feb; 117(8):2254-66. PubMed ID: 23330570 [TBL] [Abstract][Full Text] [Related]
8. Solution pH that minimizes self-association of three monoclonal antibodies is strongly dependent on ionic strength. Sule SV; Cheung JK; Antochshuk V; Bhalla AS; Narasimhan C; Blaisdell S; Shameem M; Tessier PM Mol Pharm; 2012 Apr; 9(4):744-51. PubMed ID: 22221144 [TBL] [Abstract][Full Text] [Related]
9. Application of a high-throughput screening procedure with PEG-induced precipitation to compare relative protein solubility during formulation development with IgG1 monoclonal antibodies. Gibson TJ; Mccarty K; Mcfadyen IJ; Cash E; Dalmonte P; Hinds KD; Dinerman AA; Alvarez JC; Volkin DB J Pharm Sci; 2011 Mar; 100(3):1009-21. PubMed ID: 21280052 [TBL] [Abstract][Full Text] [Related]
10. Factors affecting the viscosity in high concentration solutions of different monoclonal antibodies. Yadav S; Shire SJ; Kalonia DS J Pharm Sci; 2010 Dec; 99(12):4812-29. PubMed ID: 20821382 [TBL] [Abstract][Full Text] [Related]
11. Resolving self-association of a therapeutic antibody by formulation optimization and molecular approaches. Casaz P; Boucher E; Wollacott R; Pierce BG; Rivera R; Sedic M; Ozturk S; Thomas WD; Wang Y MAbs; 2014; 6(6):1533-9. PubMed ID: 25484044 [TBL] [Abstract][Full Text] [Related]
12. Hydrogen exchange mass spectrometry reveals protein interfaces and distant dynamic coupling effects during the reversible self-association of an IgG1 monoclonal antibody. Arora J; Hickey JM; Majumdar R; Esfandiary R; Bishop SM; Samra HS; Middaugh CR; Weis DD; Volkin DB MAbs; 2015; 7(3):525-39. PubMed ID: 25875351 [TBL] [Abstract][Full Text] [Related]
13. Intermolecular Interactions and the Viscosity of Highly Concentrated Monoclonal Antibody Solutions. Binabaji E; Ma J; Zydney AL Pharm Res; 2015 Sep; 32(9):3102-9. PubMed ID: 25832501 [TBL] [Abstract][Full Text] [Related]
14. Mechanisms of self-association of a human monoclonal antibody CNTO607. Bethea D; Wu SJ; Luo J; Hyun L; Lacy ER; Teplyakov A; Jacobs SA; O'Neil KT; Gilliland GL; Feng Y Protein Eng Des Sel; 2012 Oct; 25(10):531-7. PubMed ID: 22915597 [TBL] [Abstract][Full Text] [Related]
15. Characterization of antibody-polyol interactions by static light scattering: implications for physical stability of protein formulations. Abbas SA; Sharma VK; Patapoff TW; Kalonia DS Int J Pharm; 2013 May; 448(2):382-9. PubMed ID: 23583711 [TBL] [Abstract][Full Text] [Related]
16. Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life. Majumdar R; Esfandiary R; Bishop SM; Samra HS; Middaugh CR; Volkin DB; Weis DD MAbs; 2015; 7(1):84-95. PubMed ID: 25524268 [TBL] [Abstract][Full Text] [Related]
17. Phase separation of an IgG1 antibody solution under a low ionic strength condition. Nishi H; Miyajima M; Nakagami H; Noda M; Uchiyama S; Fukui K Pharm Res; 2010 Jul; 27(7):1348-60. PubMed ID: 20401522 [TBL] [Abstract][Full Text] [Related]
18. Developability Assessment of Engineered Monoclonal Antibody Variants with a Complex Self-Association Behavior Using Complementary Analytical and in Silico Tools. Shan L; Mody N; Sormani P; Rosenthal KL; Damschroder MM; Esfandiary R Mol Pharm; 2018 Dec; 15(12):5697-5710. PubMed ID: 30395473 [TBL] [Abstract][Full Text] [Related]